Roy Amarendra Nath, Mazumdar Ipsita
Department of Orthopaedics, Murshidabad Medical College, Berhampore, IND.
Department of Biochemistry, Jagannath Gupta Institute of Medical Sciences and Hospital, Kolkata, IND.
Cureus. 2023 Sep 21;15(9):e45662. doi: 10.7759/cureus.45662. eCollection 2023 Sep.
Osteoporosis is a chronic bone disease that develops with a decrease in bone mineral density (BMD) along with bone mass. An essential measure in the prevention of osteoporosis is the achievement of normal peak bone mass. Teriparatide (TPTD) functions as an osteoanabolic agent, exerting a dual influence on bone remodeling by modulating both osteogenesis and osteoclastogenesis. Bone mass is determined by dual-energy x-ray absorptiometry (DEXA) quantitative CT scan and has outstanding precision (within 1% to 2%) and has the ability to show the effectiveness of drug intervention.
To assess the effectiveness of TPTD treatment on BMD in osteoporosis patients.
The study is a retrospective, observational, multi-center study of 378 osteoporosis patients who were treated with 20 µg of subcutaneous TPTD every day for six months. DEXA scores of the hip joints of patients were measured both before and after TPTD treatment.
The DEXA scores of the total population pre and post-treatment were -2.75+0.58 and -2.15+0.95 respectively, with a of <0.001, which is statistically significant. In women the pre and post-treatment scores were -2.728+0.52 and -2.276+0.49, with a significant of <0.001 whereas in males, the scores were -2.756+0.72 and -2.108+1.29 respectively, with a significant of <0.05.
The six-month treatment with TPTD significantly improved DEXA scores in osteoporosis patients. DEXA score's precision and sensitivity in quantifying impact contribute to effective osteoporosis management, guiding treatment strategies for better outcomes in the Indian population. Further research is warranted to see the long-term effect of TPTD.
骨质疏松症是一种慢性骨病，随着骨矿物质密度（BMD）以及骨量的降低而发展。预防骨质疏松症的一项重要措施是达到正常的峰值骨量。特立帕肽（TPTD）作为一种骨合成代谢剂，通过调节成骨作用和破骨细胞生成对骨重塑产生双重影响。骨量通过双能X线吸收法（DEXA）定量CT扫描来测定，具有很高的精确度（在1%至2%以内），并且能够显示药物干预的效果。
评估TPTD治疗对骨质疏松症患者骨密度的有效性。
本研究是一项回顾性、观察性、多中心研究，对378例骨质疏松症患者进行了为期6个月的每日20μg皮下注射TPTD治疗。在TPTD治疗前后测量患者髋关节的DEXA评分。
总体人群治疗前后的DEXA评分分别为-2.75 + 0.58和-2.15 + 0.95，P值<0.001，具有统计学意义。女性治疗前后的评分分别为-2.728 + 0.52和-2.276 + 0.49，P值<0.001，具有显著意义；而男性的评分分别为-2.756 + 0.72和-2.108 + 1.29，P值<0.05，具有显著意义。
TPTD治疗6个月显著提高了骨质疏松症患者的DEXA评分。DEXA评分在量化影响方面的精确度和敏感性有助于有效的骨质疏松症管理，为印度人群制定更好治疗效果的治疗策略提供指导。有必要进一步研究以观察TPTD的长期效果。
